Evaluation of a Novel Combination Therapy, Based on Trifluridine/Tipiracil and Fruquintinib, against Colorectal Cancer

Chemotherapy · Published 2023-01-01 · DOI 10.1159/000528867

Authors being retrieved — see the publisher record. https://doi.org/10.1159/000528867

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year: 2023

Related articles

Combining fruquintinib with TAS-102 as a promising strategy: antitumor activity in preclinical colorectal and gastric cancer xenograft models · BMC Cancer · 2026 · Cites or is cited by this article
Daptomycin-Induced Eosinophilic Pneumonia: A Case Report and Systematic Review · Chemotherapy · 2023 · Same journal
Natural Compounds with Antimicrobial Activities in Oral Candida Infections during Head and Neck Radiotherapy · Chemotherapy · 2023 · Same journal
Changing and Evolution of Influenza Virus: Is It a Trivial Flu? · Chemotherapy · 2024 · Same journal
Gaza’s First Polio Case in 25 Years: Is Health Infrastructure Collapse Threatening Resilience? · Chemotherapy · 2024 · Same journal
Fighting Antimicrobial Resistance and Healthcare-Associated Infections in EU-JAMRAI: The One-Health Response from Italy · Chemotherapy · 2023 · Same journal
Therapeutic Drug Monitoring: A Driver to Precision Medicine for Patients with Hematological Malignancies · Chemotherapy · 2025 · Same journal
Meningococcal Conjunctivitis in a 54-Year-Old Man: Case Report and Review of the Literature · Chemotherapy · 2023 · Same journal
Circulating Endothelial Cell Kinetic in Patients with Multiple Myeloma Who Receive Autologous Hematopoietic Stem Cell Transplantation · Chemotherapy · 2023 · Same journal
Fluorodeoxyglucose-Positron Emission Tomography in Relapsed/Refractory Hodgkin Lymphoma: A Practical Approach · Chemotherapy · 2023 · Same journal